PDS Biotechnology Corporation
PDSB
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.3M
Close$
$0.21
75.9% downside
Current Fair Value
75.9% downsideOvervalued by 75.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.30 Million |
|---|---|
| Enterprise Value | $-16,351,963,051.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.74 |
| Beta | 1.56 |
| Outstanding Shares | 55,496,000 |
Return
| Return on Equity | -0.92% |
|---|---|
| Return on Assets | -0.14% |
| Return on Invested Capital | -56.22% |
Valuation & Multiples
| P/E Ratio | -1.59 |
|---|---|
| PEG | 11.83 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2 |
| Enterprise Value to Net Income | 458 |
| Total Debt to Enterprise | -0.32 |
| Debt to Equity | 1.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 330,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.88%▼ 5.93% |
|---|---|
| Total Invested | $3.05M▼ 49.67% |
| Investors Holding | 41▼ 1.00% |
ESG Score
No data
About PDS Biotechnology Corporation
CEO: Frank Bedu-Addo